comprehensive -WSS

comprehensive

author：entertainment 2025-08-12 09:08:29 - browse：68114

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： In science, is the line between industry and academia shifting?

leisure time

entertainment

WSS

Should insurance cover cosmetic surgery?

How a symptom of dementia informs our understanding of creativity

Feds fine Medicare Advantage plans for overcharging members

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Appeals court upholds limits to abortion pill

Bird flu makes raw milk dangerous to consume, mouse study finds

entertainment

comprehensive

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

NYU Langone launches private ChatGPT for its health care data

Medicare proposal to cover medical devices draws a mixed reaction

Why more medical students aren't specializing in primary care

How to save PrEP access — and even expand it

Feds fine Medicare Advantage plans for overcharging members

Drug repurposing or repositioning? The language matters

Complete sequence of Y chromosome published for first time

How one medical school became remarkably diverse

As pharma fights Medicare drug negotiation, hospitals, docs silent

Wikipedia

How to make AI work for medicine

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Neuroscience startup Neumora files for IPO

Congress: Prevent baby formula shortages by passing a new bill

How to make Best Hospitals ratings actually useful for patients

Why some fertility treatments produce more boy babies

leisure time

leisure time

entertainment

focus